Department of Orthopedics, Taizhou Hospital of Zhejiang Province, Zhejiang Universitygrid.13402.34, Linhai, China.
Zhejiang Universitygrid.13402.34 School of Medicine, Hangzhou, China.
Microbiol Spectr. 2022 Oct 26;10(5):e0054422. doi: 10.1128/spectrum.00544-22. Epub 2022 Sep 7.
Treatment of osteomyelitis is still challenging, as conventional antibiotic therapy is limited by the emergence of resistant strains and the formation of biofilms. Sonoantimicrobial chemotherapy (SACT) is a novel therapy of low-frequency and low-intensity ultrasound (LFLIU) combined with a sonosensitizer. Therefore, in our study, a sonosensitizer named emodin (EM) was proposed to be combined with LFLIU to relieve acute osteomyelitis caused by methicillin-resistant Staphylococcus aureus (MRSA) through antibacterial and antibiofilm effects. The efficiencies of different intensities of ultrasound, including single (S-LFLIU, 15 min) and multiple ultrasound (M-LFLIU, 3 times for 5 min at 4-h intervals), against bacteria and biofilms were compared, contributing to developing the best treatment regimen. Our results demonstrated that EM plus S-LFLIU or M-LFLIU (EM+S-LFLIU or EM+M-LFLIU) had significant combined bactericidal and antibiofilm effects, with EM+M-LFLIU in particular exhibiting superior antibiofilm performance. Furthermore, it was suggested that EM+M-LFLIU could produce a large amount of reactive oxygen species (ROS), destroy the integrity of the bacterial membrane and cell wall, and downregulate the expression of genes involved in oxidative stress, membrane wall synthesis, and bacterial virulence, as well as that of other related genes (, , , , , and ). studies, micro-computed tomography (micro-CT), hematoxylin and eosin (H&E) staining, enzyme-linked immunosorbent assay (ELISA), and bacterial quantification of bone tissue indicated that EM+M-LFLIU could also relieve osteomyelitis due to MRSA infection. Our work proffers an original approach to bacterial osteomyelitis treatment that weakens drug-resistant bacteria and suppresses and degrades biofilm formation through SACT, which may provide new prospects for clinical treatment. Antibiotic therapy is the first choice for clinical treatment of osteomyelitis, but the formation of bacterial biofilms and the emergence of many drug-resistant strains also create an urgent need to find an alternative treatment to effectively eliminate the infection. Recently, LFLIU has come to be considered a safe and promising method of debridement and antibacterial therapy. In this study, we found that ultrasound and EM have a significant combined antibacterial effect and , which may play an antibacterial role by stimulating the production of ROS, destroying the bacterial cell wall, and inhibiting the expression of related genes. Our study expands the body of knowledge on the antibacterial effect of drugs-specifically emodin (EM)-through combined physiotherapy. If successfully integrated into clinical practice, these methods may reduce the burden of high concentrations of drugs needed to treat bacterial biofilms and avoid the growing resistance of bacteria to antibiotics.
骨髓炎的治疗仍然具有挑战性,因为传统的抗生素治疗受到耐药菌株的出现和生物膜的形成的限制。声抗菌化疗(SACT)是一种低频低强度超声(LFLIU)与声敏剂结合的新型治疗方法。因此,在我们的研究中,提出了一种名为大黄素(EM)的声敏剂,通过抗菌和抗生物膜作用,与 LFLIU 联合用于缓解耐甲氧西林金黄色葡萄球菌(MRSA)引起的急性骨髓炎。比较了不同强度的超声,包括单次(S-LFLIU,15 分钟)和多次超声(M-LFLIU,在 4 小时间隔内 3 次 5 分钟),对细菌和生物膜的效率,有助于制定最佳治疗方案。我们的结果表明,EM 加 S-LFLIU 或 M-LFLIU(EM+S-LFLIU 或 EM+M-LFLIU)具有显著的联合杀菌和抗生物膜作用,特别是 EM+M-LFLIU 表现出优异的抗生物膜性能。此外,研究表明,EM+M-LFLIU 可以产生大量的活性氧(ROS),破坏细菌膜和细胞壁的完整性,并下调与氧化应激、膜壁合成和细菌毒力以及其他相关基因( 、 、 、 、 和 )表达相关的基因。在体内研究中,微计算机断层扫描(micro-CT)、苏木精和伊红(H&E)染色、酶联免疫吸附测定(ELISA)和骨组织细菌定量表明,EM+M-LFLIU 也可缓解 MRSA 感染引起的骨髓炎。我们的工作提供了一种治疗细菌性骨髓炎的新方法,通过 SACT 减弱耐药菌并抑制和降解生物膜的形成,这可能为临床治疗提供新的前景。抗生素治疗是骨髓炎临床治疗的首选,但细菌生物膜的形成和许多耐药菌株的出现也迫切需要寻找一种替代治疗方法来有效消除感染。最近,LFLIU 已被认为是一种安全且有前途的清创和抗菌治疗方法。在这项研究中,我们发现超声和 EM 具有显著的联合抗菌作用 和 ,这可能通过刺激 ROS 的产生、破坏细菌细胞壁和抑制相关基因的表达来发挥抗菌作用。我们的研究通过联合物理治疗扩展了药物(大黄素(EM))抗菌作用的知识体系。如果成功整合到临床实践中,这些方法可能会降低治疗细菌生物膜所需的高浓度药物的负担,并避免细菌对抗生素的耐药性不断增加。